We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Activating Cancer-Killing Immune Cells

Activating Cancer-Killing Immune Cells

Activating Cancer-Killing Immune Cells

Activating Cancer-Killing Immune Cells

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Activating Cancer-Killing Immune Cells"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cancer cells are very adaptive - they exploit this switch to hide from the immune system and avoid attack. Now researchers have shown that it is possible to use genetic editing to snip away the ‘off switch’ so that the immune system recognises cancer again. 

The team used a cutting-edge gene editing technique to remove the switch - called PD-1* - from T cells found in the tumour. They found that the immune system was then able to wipe out the cancer cells which no longer had control over the T cells. 

Researchers refer to this as ‘cutting the brakes’ and allowing immune cells to do the rest.

The study was carried out on mice in the laboratory. The researchers took T cells from the tumour, removed PD-1, multiplied the T cells and put them back into the mice and found that the tumours shrank. In experiments on melanoma and fibrosarcoma, mouse survival increased from less than 20% after 60 days without treatment to more than 70% with treatment.

Going forward, the next step will be to test this approach in clinical trials.

Dr Sergio Quezada, Head of the Immune Regulation and Cancer Immunotherapy lab at UCL Cancer Institute says: "This is an exciting discovery and means we may have a way to get around cancer's defences while only targeting the immune cells that recognise the cancer.

"While drugs that block PD-1 do show promise, this method only knocks out PD-1 on the T cells that can find the tumour - which could mean fewer side effects for patients."

*The PD-1 switch – found on T cells – is normally a safety device that stops the immune cells from wrongly attacking harmless cells.